The Med-tech specialist's Parsortix device was used by researchers in Santiago, Spain, to screen people with head and neck and non-small cell lung cancers.
They were looking for tell-tale differences, known as biomarkers, identifying suitability to be treated with a new class of drugs called MET inhibitors, specifically MET alterations in circulating tumour cells (CTCs) captured by the ANGLE technology.
These changes, mostly found in metastatic patients, have a fundamental bearing on the rate of growth and spread of the disease.
Using Parsortix, the Santiago team, part of the Liquid Biopsy Analysis Unit at the Health Research Institute, was able to identify MET positive CTCs.
The leading antibody approach to harvesting cancer cells had a “significantly lower” success rate in this regard and failed to establish a relationship between MET expression in the CTCs and survival rates.
ANGLE said the research suggested the Parsortix system could be used as part of a biomarker approach in cancer drug trials of MET inhibitors.
It then might be deployed as a companion diagnostic to identify patients likely to respond to the MET inhibitor drugs.
"The analysis of MET status on CTCs using Parsortix is a new and promising area of investigation for cancer treatment,” Andrew Newland, ANGLE’s chief executive said in a statement.
“This research further demonstrates Parsortix's applicability and we will now consider how we can add it to our sample-to-answer imaging solutions for use in pharma services cancer drug trials," he added.